Consistently, EZH2i promoted T cells activation (Granzyme B, IFNγ) and inhibited their exhaustion (LAG3) in tumor treated with chemotherapy (Fig. 6F, G), with similar phenomena as chemoimmunotherapy (Figure S5G). This evidence concerns the gene IFNG and neoplasm.